Jove
Visualize
Contact Us

Related Concept Videos

Half-life of a Reaction02:42

Half-life of a Reaction

The half-life of a reaction (t1/2) is the time required for one-half of a given amount of reactant to be consumed. In each succeeding half-life, half of the remaining concentration of the reactant is consumed. For example, during the decomposition of hydrogen peroxide, during the first half-life (from 0.00 hours to 6.00 hours), the concentration of H2O2 decreases from 1.000 M to 0.500 M. During the second half-life (from 6.00 hours to 12.00 hours), the concentration decreases from 0.500 M to...
Radioactive Decay and Radiometric Dating02:48

Radioactive Decay and Radiometric Dating

Radioactivity is a spontaneous disintegration of an unstable nuclide and is a random process, as all the nuclei in the sample do not decay simultaneously. The number of disintegrations per unit time is called the activity (A), which is directly proportional to the number of nuclei in the sample. The decay constant (λ) is an average probability of decay per nucleus in unit time.
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the lowest drug...
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution01:09

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated from...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Network for Optimization of Veterinary Antimicrobial Therapy (ENOVAT) 2025 guidelines for surgical antimicrobial prophylaxis in dogs and cats.

The Journal of small animal practice·2025
Same author

Understanding the rationale for metronidazole use in dogs and cats.

The Journal of small animal practice·2025
Same author

Antimicrobial prophylaxis in companion animal surgery: A scoping review for European Network for Optimization of Antimicrobial Therapy (ENOVAT) guidelines.

Veterinary journal (London, England : 1997)·2024
Same author

A new LC/MS method for specific determination of human systemic exposure to bisphenol A, F and S through their metabolites: Application to cord blood samples.

Environment international·2021
Same author

Modeling chlordecone toxicokinetics data in growing pigs using a nonlinear mixed-effects approach.

Chemosphere·2020
Same author

Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"

Clinical pharmacokinetics·2019
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 27, 2026

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

Plasma terminal half-life.

P L Toutain1, A Bousquet-Mélou

  • 1UMR 181 Physiopathologie et Toxicologie Expérimentales INRA/ENVT, Ecole Nationale Vétérinaire de Toulouse, Toulouse cedex 03, France. pl.toutain@envt.fr

Journal of Veterinary Pharmacology and Therapeutics
|December 17, 2004
PubMed
Summary
This summary is machine-generated.

Terminal plasma half-life determines drug accumulation and concentration fluctuations in multiple dosing. It reflects elimination when absorption isn't limiting, but absorption when it is (flip-flop pharmacokinetics).

More Related Videos

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh
10:42

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh

Published on: May 3, 2019

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Experiment Videos

Last Updated: May 27, 2026

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh
10:42

Preparing an Isotopically Pure 229Th Ion Beam for Studies of 229mTh

Published on: May 3, 2019

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Area of Science:

  • Pharmacokinetics
  • Drug Metabolism
  • Clinical Pharmacology

Background:

  • Terminal plasma half-life is a critical pharmacokinetic parameter.
  • Understanding half-life influences drug dosing and therapeutic outcomes.

Purpose of the Study:

  • To clarify the precise definition and determinants of terminal plasma half-life.
  • To differentiate its role in various pharmacokinetic scenarios, including flip-flop pharmacokinetics.
  • To highlight its significance in multiple dosing regimens.

Main Methods:

  • Conceptual analysis of pharmacokinetic principles.
  • Review of established definitions and parameters like plasma clearance and distribution.
  • Examination of absorption-limited versus elimination-limited scenarios.

Main Results:

  • Terminal plasma half-life is defined by the time to halve plasma concentration post-pseudo-equilibrium, not dose elimination.
  • It is influenced by plasma clearance and distribution when absorption is not limiting.
  • In absorption-limited (flip-flop) conditions, it reflects absorption rate and extent, not elimination.

Conclusions:

  • Terminal plasma half-life is a hybrid parameter with distinct interpretations based on absorption influence.
  • Accurate understanding is crucial for predicting drug accumulation, concentration variability, and time to equilibrium in multiple dosing.
  • Distinguishing between elimination- and absorption-driven half-life is vital for effective clinical application.